JGP Global Gestao de Recursos Ltda. boosted its stake in shares of TESARO Inc (NASDAQ:TSRO) by 65.6% during the first quarter, according to its most recent 13F filing with the SEC. The fund owned 2,860 shares of the biopharmaceutical company’s stock after buying an additional 1,133 shares during the period. TESARO accounts for 0.4% of JGP Global Gestao de Recursos Ltda.’s portfolio, making the stock its 11th largest position. JGP Global Gestao de Recursos Ltda.’s holdings in TESARO were worth $440,000 as of its most recent SEC filing.
Several other institutional investors have also recently modified their holdings of TSRO. Capital Analysts LLC purchased a new position in shares of TESARO during the fourth quarter valued at about $134,000. Massmutual Trust Co. FSB ADV purchased a new position in shares of TESARO during the fourth quarter valued at about $134,000. Citizens Financial Group Inc RI purchased a new position in shares of TESARO during the third quarter valued at about $154,000. Pacer Advisors Inc. purchased a new position in shares of TESARO during the third quarter valued at about $216,000. Finally, First Citizens Bank & Trust Co. purchased a new position in shares of TESARO during the first quarter valued at about $288,000. Institutional investors own 98.48% of the company’s stock.
Shares of TESARO Inc (NASDAQ:TSRO) traded down 1.86% on Friday, hitting $152.34. The stock had a trading volume of 905,145 shares. TESARO Inc has a one year low of $36.71 and a one year high of $192.94. The company’s market capitalization is $8.21 billion. The firm has a 50 day moving average price of $144.45 and a 200 day moving average price of $149.10.
TESARO (NASDAQ:TSRO) last released its quarterly earnings data on Tuesday, May 9th. The biopharmaceutical company reported ($2.55) EPS for the quarter, missing the Zacks’ consensus estimate of ($2.26) by $0.29. TESARO had a negative net margin of 798.68% and a negative return on equity of 141.88%. The firm had revenue of $3.10 million during the quarter, compared to the consensus estimate of $3.84 million. During the same quarter in the prior year, the company earned ($2.22) EPS. TESARO’s quarterly revenue was up 909.8% on a year-over-year basis. On average, equities research analysts predict that TESARO Inc will post ($8.72) earnings per share for the current fiscal year.
Several equities analysts have recently issued reports on the company. Leerink Swann reiterated a “market perform” rating on shares of TESARO in a research report on Monday, March 20th. Citigroup Inc lifted their price target on TESARO from $151.00 to $232.00 and gave the company a “buy” rating in a research report on Thursday, February 9th. Wedbush lifted their price target on TESARO from $164.00 to $174.00 and gave the company an “outperform” rating in a research report on Tuesday, March 28th. Vetr upgraded TESARO from a “buy” rating to a “strong-buy” rating and set a $178.33 price target on the stock in a research report on Monday, March 27th. Finally, Robert W. Baird cut TESARO from an “outperform” rating to a “neutral” rating and lifted their target price for the stock from $127.00 to $182.00 in a report on Monday, February 27th. Seven research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $172.30.
In related news, SVP Martin H. Jr. Huber sold 829 shares of the company’s stock in a transaction on Monday, April 3rd. The shares were sold at an average price of $153.02, for a total value of $126,853.58. Following the completion of the sale, the senior vice president now owns 6,522 shares in the company, valued at approximately $997,996.44. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, VP Edward C. English sold 10,000 shares of the company’s stock in a transaction on Monday, March 6th. The shares were sold at an average price of $178.06, for a total transaction of $1,780,600.00. Following the completion of the sale, the vice president now owns 5,396 shares of the company’s stock, valued at approximately $960,811.76. The disclosure for this sale can be found here. In the last 90 days, insiders sold 16,432 shares of company stock valued at $2,902,602. 40.50% of the stock is owned by corporate insiders.
TESARO Company Profile
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc and related companies with MarketBeat.com's FREE daily email newsletter.